LDS/Medical Tests/Pancreastatin

Pancreastatin

Pancreastatin is a 49–amino acid peptide generated from proteolytic cleavage of chromogranin A (CgA), a secretory protein found in neuroendocrine cells. Several biologically active peptides, including vasostatins, catestatin, and serpinin, are also released during CgA processing. Originally identified as an inhibitor of glucose-induced insulin secretion from pancreatic islets, pancreastatin plays a broader role in regulating glucose and lipid metabolism, calcium homeostasis, cardiovascular function, and immune processes. Pancreastatin inhibits insulin release by decreasing intracellular calcium levels and reducing cAMP production. Elevated circulating levels have been associated with insulin resistance and impaired glucose tolerance, while experimental data suggest potential therapeutic implications for diabetes.

Clinically, pancreastatin is increasingly recognized as a biomarker for neuroendocrine tumors (NETs), with levels reflecting tumor activity and disease burden. Unlike chromogranin A, pancreastatin is less influenced by confounding conditions such as proton pump inhibitor (PPI) therapy or renal insufficiency, making it a more specific marker for NET surveillance.

  • As an aid in diagnosis and monitoring neuroendocrine tumors
  • Aid in monitoring insulin resistance and diabetes mellitus
  • May provide a prognostic value in pancreatic dysfunction

Increased in:

  • Neuroendocrine tumors
  • Pancreatitis
  • Pancreatic adenocarcinoma
  • Insulinoma
  • Diabetes mellitus
  • Chronic kidney disease

Decreased in:

  • Pancreatic insufficiency
  • Acromegaly post treatment
  • Hypoinsulinemia
  • Severe hypoglycemia

10-135 pg/mL

Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).

Plasma, Z-tube.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 60 days
Chromogranin A (CgA), Comprehensive metabolic panel, Complete blood count (CBC), C-peptide, Helicobacter pylori antigen/antibody testing, Stool fat analysis (if malabsorption suspected), Gastric/duodenal biopsy in Zollinger–Ellison syndrome evaluation.

3 - 7 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login